SCHEMBL1557719

SCHEMBL1557719

COc1ccc(CC=O)cc1CCl

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46
PPARA Q07869 1/20 0.46
ALOX5 P09917 4/20 0.43
GABRA1 P14867 3/20 0.43
GABRB2 P47870 3/20 0.43
CNR2 P34972 2/20 0.43
PTGS1 P23219 2/20 0.41
TTR P02766 2/20 0.41
CA2 P00918 1/20 0.40
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP3A4 P08684 1/20 0.39
AR P10275 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
MCL1 Q07820 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24021272 0.86 ALDH1A1 (0.49) ALDH1A1PPARGPPARDPPARAALOX5
SCHEMBL5598123 0.83 TTR (0.54) ALDH1A1PPARGPPARDPPARATTR
SCHEMBL30776597 0.83 TTR (0.54) ALDH1A1PPARGPPARDPPARATTR
SCHEMBL5504133 0.83 ALDH1A1 (0.43) ALDH1A1GABRA1GABRB2
SCHEMBL4615833 0.82 AKT1 (0.45) ALDH1A1PPARGPPARDPPARAALOX5
SCHEMBL6141100 0.81 ALDH1A1 (0.56) ALDH1A1PPARGPPARDPPARAALOX5
SCHEMBL5509230 0.81 MAPT (0.46) ALDH1A1GABRA1GABRB2CNR2PKM
SCHEMBL557409 0.80 ALDH1A1 (0.69) ALDH1A1PPARGPPARDPPARAPTGS1
SCHEMBL30644304 0.80 ALDH1A1 (0.69) ALDH1A1PPARGPPARDPPARAPTGS1
SCHEMBL31422467 0.79 HSD17B10 (0.62) ALDH1A1PPARGPPARDPPARAALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303875-A2 COMPOSITIONS WITH AND PROCESS FOR METHYLMORPHOLIN-SUBSITUTED PYRIDO[2,3-D]PYRIMIDINES AstraZeneca AB (SE) 2011-04-06 EP disclosed
WO-2009153597-A2 COMPOSITION AND PROCESS - 356 ASTRAZENECA AB (SE) 2009-12-23 WO disclosed
EP-1784182-A1 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2007-05-16 EP disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
WO-2006021418-A1 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2006-03-02 WO disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 EP disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed